Left to Right: Lina Gasiūnaitė, Andy Hall-Ponselè, John McNicol (Kelvin Capital), Fiona Marshall & Ross McDermid
Biotangents, a Scottish biotech located on Pentlands Science Park in Midlothian Science Zone, has secured £2.2m of new funding and strengthened the management team and Board to further support the next phase of development and roll-out of its ‘on farm’ rapid disease technology.
Biotangents has secured £2.2m of new funding made up from £1.6m from the UK Government’s Innovate UK innovation loans programme and a further £600k from a funding round lead by the investment syndicate Kelvin Capital and with Scottish Enterprise participation to support the development and roll-out of its ‘on farm’ rapid disease detection technology.
The company also secured £1.2m in August 2021 in a successful funding round also led by Kelvin Capital, following an initial £1.5m in May 2019. Kelvin Capital represents private investors in the UK, Europe, and the USA.
The business has also confirmed the appointment of Fiona Marshall as CEO and Ross McDermid as Director of Commercialisation to the company’s Board. Both have successful commercial careers in the animal health and veterinary sectors and strengthen the existing Board and senior management team. In addition, Professor Richard Hammond has joined the Board as Non-Exec Director.
Biotangents’ Isothermal technology can be applied to the rapid detection of a wide range of diseases in Animal Health including Bovine Viral Diarrhoea (BVD) and Mastitis. The award winning AmpliSpec™ Mastitis diagnostic test will dramatically cut the detection time for Mastitis from the current period of several days to just a few hours.
Current Mastitis testing requires a sample to be sent to an external laboratory whereas Biotangents’ new technology will provide a specific pathogen diagnosis that can be carried out immediately, either on the farm or in a veterinary clinic, enabling rapid and targeted treatment for infected cattle.
Mastitis currently costs the global farming industry up to £23bn each year, and the average dairy farm in the UK anywhere between £7,000 and £25,000 per year. The financial costs of failing to diagnose BVD early can cost farmers up to £470 per animal, and it is responsible for £61m of losses each year in the UK alone. Key milk producing regions globally encounter productivity challenges due to mastitis and Biotangents plan to make this technology available globally.
“Rapid diagnosis on the farm and in the veterinary clinic is a step change in the treatment and prevention of Mastitis and the consequent improvement in animal husbandry. Critically it allows vets to promptly decide on the most effective treatment programme including the correct antibiotic to be administered and length of treatment period, and lets farmers implement prompt procedures to minimise further infection within the herd.”
Ian Hamilton, Chairman at Biotangents and holder of several senior positions within the agricultural industry
“In addition to our forthcoming lab based AmpliSpec ™ BVD and Mastitis products, the new funding will enable the next phase of our product development delivering our new AmpliSpec™ platform directly to the veterinary and farming sectors.
“Beyond Mastitis further assays will be developed for use on this platform. We all know that the financial impact of Mastitis is significant but it also has a huge impact on animal welfare and sustainability. The platform will provide accurate diagnosis between milking allowing the Vet and Farmer to quickly determine the most appropriate treatment for each individual cow, including specific antibiotic treatment. We recognise the positive impact this will have on antimicrobial resistance, ultimately reducing antibiotic usage.”
Fiona Marshall, CEO at Biotangents
“We have supported Biotangents since 2017 and are delighted to continue that and welcome the strengthening of the existing operational team and the company’s Board. This disruptive technology will bring additional benefits to the global dairy sector and wider AgriTech sector because rapid diagnostic technology brings financial benefits to farmers and dramatically improves animal welfare.”
John McNicol, director of Kelvin Capital
“Scotland is globally renowned for its strengths in life sciences, owing that reputation in part to innovative biotechnology businesses such as Biotangents. Working alongside companies in this sector to progress ground-breaking diagnostics technology, and in turn investing in Scotland’s wider rural economy, is a priority for Scottish Enterprise. We are delighted to support Biotangents on their journey taking their product range from Scottish laboratory to new international markets.”
Kerry Sharp, Director of Entrepreneurship and Investment at Scottish Enterprise
Biotangents’ AmpliSpec™ Mastitis diagnostic test was selected by an international panel of experts as the winner of the ‘Production Animal’ Animal Health Innovation Award 2021 at Animal Health Innovation Europe, one of the most prestigious awards in the industry